ILK-IN-2

ILK-IN-2 (OSU-T315 analog) is an oral PDK2 inhibitor and also an ILK inhibitor, with an IC50 of 0.6 μM. ILK-IN-2 induces cell autophagy and apoptosis, showing anti-tumor activity. ILK-IN-2 directly abolishes AKT activation by preventing AKT from translocating to lipid rafts, triggering Caspase-dependent apoptosis in chronic lymphocytic leukemia (CLL) and extending the lifespan in TCL1 mouse models[1][2].

Product Specifications

CAS Number

[1333146-24-9]

Product Name Alternative

OSU-T315 analog

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Ser/Thr Kinase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ILK-IN-2.html

Purity

99.41

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(NC)CCC1=NN(C2=CC=C(N3CCNCC3)C=C2)C(C4=CC=C(C5=CC=C(C(F)(F)F)C=C5)C=C4)=C1

Molecular Formula

C30H30F3N5O

Molecular Weight

533.59

Precautions

H302, H315, H319, H335

References & Citations

[1]Ta-Ming Liu, et al. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood. 2015 Jan 8;125 (2) :284-95.|[2]Su-Lin Lee, et al. Identification and characterization of a novel integrin-linked kinase inhibitor. J Med Chem. 2011 Sep 22;54 (18) :6364-74.